Company research / GOSS

Gossamer Bio, Inc. (GOSS)

CIK 0001728117 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Gossamer Bio, Inc. reported revenue of $48.47M. Revenue fell 57.7% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $53.29M.

Key ratios (year ended 2025-12-31)

-352.2%
Operating margin
-351.5%
Net margin
-57.7%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-09-28

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Revenue$53.29M$48.47M$114.70M$0$0n/an/an/an/an/a
R&D Expense$163.96M$174.09M$138.49M$135.30M$170.92M$170.27M$160.85M$143.40M$55.28M$891.0K
Operating Income-$166.09M-$170.73M-$59.92M-$183.76M-$218.59M-$216.12M-$233.96M-$186.14M-$148.99M-$6.65M
Depreciation & Amortizationn/a$24.0K$833.0K$1.61M$1.83M$1.74M$1.41M$917.0K$297.0Kn/a
EBITDAn/a-$170.70M-$59.09M-$182.15M-$216.76M-$214.38M-$232.55M-$185.22M-$148.70Mn/a
Net Income-$125.22M-$170.37M-$56.53M-$179.82M-$229.38M-$234.00M-$243.36M-$180.31M-$146.97M-$6.77M
EPS (Diluted)n/a-$0.75-$0.25-$1.18-$2.71-$3.13-$3.55-$3.29n/an/a
Total Assets$76.87M$172.25M$315.29M$311.92M$272.45M$343.66M$539.43M$426.60M$239.42Mn/a
Total Liabilities$170.90M$295.01M$285.80M$249.15M$260.37M$222.19M$218.75M$74.12M$21.12Mn/a
Long-Term Debtn/an/an/an/an/an/an/a$28.46Mn/an/a
Shareholders' Equity-$94.03M-$122.76M$29.49M$62.77M$12.08M$121.46M$320.68M$352.49M-$120.07M-$6.86M
Cash & Equivalents$41.15M$37.73M$46.07M$32.11M$111.97M$183.40M$486.06M$135.03M$105.22Mn/a
Operating Cash Flow-$162.63M-$171.27M-$3.47M-$159.16M-$187.03M-$188.89M-$176.36M-$144.83M-$51.04M-$5.75M
Capital Expenditures$0$79.0K$0$0$410.0K$1.55M$1.50M$2.97M$3.49Mn/a
Free Cash Flow-$162.63M-$171.34M-$3.47M-$159.16M-$187.44M-$190.44M-$177.86M-$147.80M-$54.53Mn/a
Shares Outstanding488.85M233.68M226.60M225.41M94.42M75.75M73.87M61.64M8.05Mn/a
Weighted Average Diluted Sharesn/a228.52M226.23M152.62M84.57M74.84M68.51M54.74Mn/an/a
EPS (Basic)n/a-$0.75-$0.25-$1.18-$2.71-$3.13-$3.55-$3.29n/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView